Lead Product(s) : Ecnoglutide,Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Sciwind Biosciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : In the terms of the agreement, Sanofi granted exclusive worldwide rights to Sciwind to develop, manufacture and commercialize Sanofi's GIP receptor agonists including XW003, for all applicable indications.
Product Name : XW003
Product Type : Peptide
Upfront Cash : Undisclosed
November 30, 2021
Lead Product(s) : Ecnoglutide,Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Sciwind Biosciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Pramlintide,Exenatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Three patent families have been filed to cover novel hormonal combinations: pramlintide-exenatide and glucagon-exenatide-both combinations demonstrated promising effects in obesity treatment.
Product Name : PramExe
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
May 26, 2021
Lead Product(s) : Pramlintide,Exenatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable